Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Lancet Oncol. 2015 Jun 9;16(7):775–786. doi: 10.1016/S1470-2045(15)00047-9

Figure 1. CONSORT diagram for the Costa Rica Vaccine Trial and PATRICIA trial combined.

Figure 1

This CONSORT contains women who were randomized into both trials, stratified by vaccine arm and number of doses received. 1Women were excluded if they had less than 12 months follow-up time (time total vaccinated cohort, T-TVC). 2Women were additionally excluded if their enrollment cervical status was HPV16 AND 18 DNA-positive (or missing) or they had fewer than 300 days between first and last PCR result; modified total vaccinated cohort (M-TVC) evaluating HPV16/18-related endpoints. 3Women were further excluded from the TVC-naïve if their cervical status at enrollment was HPV DNA-positive for any oncogenic type (or missing), or HPV16 or 18 seropositive (or missing), or had enrollment cytology abnormal (or missing).